HomeNaldemedine

Naldemedine

Also known as: Symproic

Route: Oral

Check Naldemedine Interactions →
20 interactions on record

Naldemedine has 20 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Fluconazole, Itraconazole. Patients taking Naldemedine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
20
Major
6
Moderate
14

Major (6)

  • Naldemedine + CarbamazepineStrong CYP3A inducer causing significant decrease in plasma naldemedine concentrations, which may reduce efficacy.
  • Naldemedine + FluconazoleModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + ItraconazoleModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + PhenytoinStrong CYP3A inducer causing significant decrease in plasma naldemedine concentrations, which may reduce efficacy.
  • Naldemedine + RifampinStrong CYP3A inducer causing significant decrease in plasma naldemedine concentrations, which may reduce efficacy.
  • Naldemedine + St. John'S WortStrong CYP3A inducer causing significant decrease in plasma naldemedine concentrations, which may reduce efficacy.

Moderate (14)

  • Naldemedine + AmiodaroneP-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
  • Naldemedine + AprepitantModerate CYP3A inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
  • Naldemedine + AtazanavirModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + CaptoprilP-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical I
  • Naldemedine + ClarithromycinModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + CyclosporineP-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
  • Naldemedine + DiltiazemModerate CYP3A inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
  • Naldemedine + ErythromycinModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + KetoconazoleModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + QuercetinP-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
  • Naldemedine + QuinidineP-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
  • Naldemedine + RitonavirModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + SaquinavirModerate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazo
  • Naldemedine + VerapamilP-glycoprotein inhibitor increasing plasma naldemedine concentrations; monitor for adverse reactions.
Naldemedine + Fluconazole⚠️Major

Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . Strong CYP3A inducers (e.g., rifampin) : Decreased naldemedine concentrations; avoid concomitant use ( 7 ) Other opioid antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use ( 7 ) Moderate (e.g., fluconazole) and strong (e.g., itraconazole) CYP3A4 inhibitors : Increased naldemedine concentrations; monitor for adverse reactions ( 7 ) P-gp inhibitors (e.g., cyclosporine) : Monitor for adverse reactions ( 7 )

Naldemedine + Itraconazole⚠️Major

Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . Strong CYP3A inducers (e.g., rifampin) : Decreased naldemedine concentrations; avoid concomitant use ( 7 ) Other opioid antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use ( 7 ) Moderate (e.g., fluconazole) and strong (e.g., itraconazole) CYP3A4 inhibitors : Increased naldemedine concentrations; monitor for adverse reactions ( 7 ) P-gp inhibitors (e.g., cyclosporine) : Monitor for adverse reactions ( 7 )

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.